ARCHIVES

ACS Board allocated $37.5 Million to Research; More Coming

This article is from The Cancer Letter archive.

Vol. 13 No. 08 | February 20, 1987

Download PDF Visit The Full Archive

Related Articles

GAO Report On NCI Cancer Control Contracts (Continued)

August 1, 1980

Merck Serono Cancels Tecemotide Program In NSCLC, Including Two Phase III Trials

September 26, 2014

ACS President Calls On Physicians To Take Advantage Of “Untapped Opportunities” In Cancer Prevention

March 27, 1987

NCCS Networker Volume 3 Issue 3, Summer 1989

June 13, 1989

NAB Approves Subcommittee Recommendations On Organ Site Program – NIH Review, One Headquarters

May 21, 1982

High Response Rate of Hairy Cell Leukemia Patients to Immunotoxin Treatment In Phase I

April 27, 2001